Abstract:Aim/Background: In the LL3 (345 pts recruited globally) and LL6 (364 Asian-only pts [no Japanese]) phase 3 randomized trials, first-line A, an irreversible ErbB family blocker, significantly improved OS vs cisplatin/pemetrexed (33.3 vs 21.1 months; HR 0.54; p = 0.0015) and gemcitabine/cisplatin (31.4 vs 18.4 months; HR 0.64; p = 0.023) in pts with advanced NSCLC harboring EGFR Del19 mut; no significant difference in OS was observed in EGFR L858R mut-positive patients in either study. Pre-planned subgroup analyses of OS by race including Asian, non-Asian (LL3 only), and Japanese patients (LL3 only) are reported. Methods: In each study, pts were randomized (2:1) to 40 mg/day oral A or up to 6 cycles of CT, stratified by EGFR mut (Del19/L858R/other) and race (LL3 only; Asian/non-Asian). Results: Significant improvements in OS in NSCLC pts harboring EGFR Del19 mut were observed in all race subgroups analyzed. In the Asian subgroup of LL3, median OS in Del19 pts (n = 123) was 33.3 months with A vs 22.9 months with CT (HR 0.57 [95% CI 0.36–0.90]; p = 0.015). In the non-Asian subgroup of LL3, median OS in Del19 pts (n = 46) was 33.6 months with A vs 20.0 months with CT (HR 0.45 [95% CI 0.21–0.95]; p = 0.03). In the Japanese subgroup of LL3, median OS in Del19 pts (n = 39) was 46.9 months with A vs 31.5 months with CT (HR 0.34 [95% CI 0.13–0.87]; p = 0.018). Significant improvement in OS with A vs CT was also observed in the combined analysis of Asian Del19 pts (n = 309) in LL3 and LL6 (median 31.7 vs 21.1 months; HR 0.61 [95% CI 0.46–0.82]; p = 0.001). No statistically significant difference in OS with A vs CT was observed for L858R mut pts in any of the race subgroups analyzed. Subsequent EGFR tyrosine kinase inhibitor therapy was received by 69%, 65% and 100% of non-Asian, Asian and Japanese patients, respectively, in the CT arm. Conclusions: Significant improvement in OS with first-line A vs CT in pts with NSCLC harboring EGFR Del19 mut was demonstrated in subgroup analyses of Asian, non-Asian, and Japanese pts. These findings are consistent with analysis of the overall LL3 and LL6 pooled population. Clinical trial identification: NCT00949650; NCT01121393 Disclosure: Y.-L. Wu: honoraria from Boehringer Ingelheim, Roche, AstraZeneca, Eli Lilly and Pfizer. L.V. Sequist: advisory board involvement in an uncompensated role for Boehringer Ingelheim, AstraZeneca, Clovis, Novartis, Genetech, Merrimack, and Taiho. M. Schuler: advisory board participation for AstraZeneca, Boehringer Ingelheim, Celgene, Lilly and Novartis; corporate-sponsored research for Boehringer Ingelheim and Novartis; and honoraria from Alexion, Boehringer Ingelheim, Celgene, Lilly, Novartis and Pfizer. N. Yamamoto: advisory board involvement, corporate-sponsored research and honoraria with Boehringer Ingelheim. K. O'Byrne, V. Hirsh: honoraria for advisory board involvement with Boehringer Ingelheim. T. Mok: Speaker's Bureau participant with AstraZeneca, Roche/Genentech, Pfizer, Eli Lilly, Boehringer Ingelheim, MSD, Amgen, Janssen, Clovis Oncology, GSK, and Novartis; advisory board participation for AstraZeneca, Roche/Genentech, Pfizer, Eli Lilly, BI, Merck Serono, MSD, Janssen, Clovis Oncology, BioMarin, GSK, Novartis, SFJ Pharmaceutical, and ACEA Biosciences, Inc.; honoraria from AstraZeneca, Roche/Genentech, Pfizer, Eli Lilly, BI, MSD, Amgen, Janssen, Clovis Oncology, GSK, and Novartis; and major stock shareholder in Sanomics Ltd. V. Zazulina: employment with Boehringer Ingelheim. J.C.-H. Yang: advisory board participation for Astrazeneca, Roche/Genentech, Boehringer Ingelheim, MSD, Merck Serono, Novartis, Clovis Oncology, Eli Lilly, Bayer, Celgene, Astellas, Innopharma, and Ono Pharmaceutical; and honoraria from Astrazeneca, Roche/Genentech, Boehringer Ingelheim, MSD, Merck Serono, Novartis, Clovis Oncology, Eli Lilly, Bayer, Celgene, Astellas, Innopharma, and Ono Pharmaceutical. All other authors have declared no conflicts of interest.

OA11.07 Chemotherapy Plus EGFR-TKI As First-Line Treatment Provides Better Survival for EGFR Mutation NSCLC Patients: Update Data for NCT02148380

Chemotherapy Plus EGFR-TKI as First-Line Treatment Provides Better Survival for Advanced EGFR-Positive Lung Adenocarcinoma Patients: Updated Data and Exploratory In Vitro Study

Combination of Chemotherapy and Gefitinib As First-Line Treatment for Patients with Advanced Lung Adenocarcinoma and Sensitive Egfr Mutations: A Randomized Controlled Trial

Gefitinib or Erlotinib Vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival

Study of Gefitinib and Pemetrexed As First-Line Treatment in Patients with Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutation

The efficacy and tolerability of combining pemetrexed-based chemotherapy with gefitinib in the first-line treatment of non-small cell lung cancer with mutated EGFR: A pooled analysis of randomized clinical trials

Effect of Combined Therapy Inhibiting EGFR and VEGFR Pathways in Non–Small-cell Lung Cancer on Progression-free and Overall Survival

Continuing EGFR-TKI in Combination with Super-Selected Arterial Infusion Chemotherapy Beyond RECIST PD for Patients with Advanced EGFR Positive Mutation Non-Small Cell Lung Cancer.

Gefitinib Plus Chemotherapy Versus Placebo Plus Chemotherapy in Egfr-Mutation- Positive Non-Small-Cell Lung Cancer after Progression on First-Line Gefitinib (impress): A Phase 3 Randomised Trial

Epidermal Growth Factor Receptor‐tyrosine Kinase Inhibitor Therapy is Effective As First‐line Treatment of Advanced Non‐small‐cell Lung Cancer with Mutated EGFR: A Meta‐analysis from Six Phase III Randomized Controlled Trials

Mefatinib As First-Line Treatment of EGFR Sensitizing Mutation-Positive Non-Small-cell Lung Cancer: A Phase III Efficacy and Biomarker Study.

Continuation of gefitinib plus chemotherapy prolongs progression-free survival in advanced non-small cell lung cancer patients who get acquired resistance to gefitinib without T790M mutations.

Superior Efficacy of Immunotherapy‐based Combinations over Monotherapy for EGFR‐mutant Non‐small Cell Lung Cancer Acquired Resistance to EGFR‐TKIs

445P Overall Survival (OS) with Afatinib (A) Vs Chemotherapy (CT) in Patients (pts) with NSCLC Harboring EGFR Mutations (mut): Subgroup Analyses by Race in LUX-Lung 3 (LL3) and LUX-Lung 6 (LL6)

Pemetrexed Versus Gefitinib As a Second-Line Treatment in Advanced Nonsquamous Nonsmall-Cell Lung Cancer Patients Harboring Wild-Type EGFR (CTONG0806): a Multicenter Randomized Trial.

Randomized controlled trial of chemotherapy plus geiftinib as ifrst-line treatment for patients with advancedEGFR mutation-positive lung adenocarcinoma

P1.03-052 Comparing EGFR-TKI with EGFR-TKI Plus Chemotherapy As 1st Line Treatment in Advanced NSCLC Patients with Both Mutated EGFR and Bim Polymorphism

Pemetrexed/carboplatin Plus Gefitinib As a First-Line Treatment for EGFR-mutant Advanced Nonsmall Cell Lung Cancer: a Bayesian Network Meta-Analysis

Combination of EGFR-TKIs with Chemotherapy Versus Chemotherapy or EGFR-TKIs Alone in Advanced NSCLC Patients with EGFR Mutation